Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolpidem versus amantadine versus placebo for consciousness recovery after diffuse axonal injury
IRCT20191026045243N1Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in Diffuse axonal injury (DAI) comparing zolpidem, amantadine and placebo (3 arms). Primary endpoint: Increased level of consciousness in patients with diffuse axonal injury. Started Dec 2019; status: completed.
02
Drugs
zolpidemamantadine
03
Conditions
Diffuse axonal injury (DAI)
Beyond the preview
Go deeper on IRCT20191026045243N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191026045243N1.